Woodline Partners’s Nurix Therapeutics NRIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $1.14M | Buy |
100,271
+67
| +0.1% | +$763 | 0.01% | 791 |
|
|
2025
Q1 | $1.19M | Sell |
100,204
-238,258
| -70% | -$2.83M | 0.01% | 746 |
|
|
2024
Q4 | $6.38M | Buy |
338,462
+1,583
| +0.5% | +$29.8K | 0.04% | 435 |
|
|
2024
Q3 | $7.57M | Buy |
336,879
+34,992
| +12% | +$786K | 0.06% | 335 |
|
|
2024
Q2 | $6.3M | Buy |
+301,887
| New | +$6.3M | 0.06% | 312 |
|
|
2022
Q2 | – | Sell |
-219,281
| Closed | -$3.07M | – | 858 |
|
|
2022
Q1 | $3.07M | Sell |
219,281
-373,660
| -63% | -$5.23M | 0.05% | 308 |
|
|
2021
Q4 | $17.2M | Buy |
592,941
+455,540
| +332% | +$13.2M | 0.25% | 119 |
|
|
2021
Q3 | $4.12M | Buy |
+137,401
| New | +$4.12M | 0.07% | 283 |
|
|
2021
Q1 | – | Sell |
-161,211
| Closed | -$5.3M | – | 459 |
|
|
2020
Q4 | $5.3M | Buy |
161,211
+17,124
| +12% | +$563K | 0.14% | 154 |
|
|
2020
Q3 | $5.03M | Buy |
+144,087
| New | +$5.03M | 0.16% | 128 |
|